Lexaria Bioscience

Kelowna, Canada Founded: 2004 • Age: 22 yrs
Patented drug delivery technology is developed for bioactive molecules.
Request Access

About Lexaria Bioscience

Lexaria Bioscience is a company based in Kelowna (Canada) founded in 2004.. The company has 7 employees as of August 31, 2024. Lexaria Bioscience offers products and services including DehydraTECH. Lexaria Bioscience operates in a competitive market with competitors including Focus Financial Partners, Alera Group, Avidity Biosciences, Sutro Biopharma and Wintrust, among others.

  • Headquarter Kelowna, Canada
  • Employees 7 as on 31 Aug, 2024
  • Stage Public
  • Sectors
    Healthcare
    Financial Services
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Lexaria Bioscience Corp.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Financial Services → Investment Management & Advisory
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
    $464.28 K
    105.24
    as on Aug 31, 2024
  • Net Profit
    $-5.8 M
    13.05
    as on Aug 31, 2024
  • EBITDA
    $-5.62 M
    12.04
    as on Aug 31, 2024
  • Latest Funding Round
    $1.57 M (USD), Post-IPO

    Oct 04, 2023

  • Investors
  • Employee Count
    7

    as on Aug 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Lexaria Bioscience

Lexaria Bioscience is a publicly listed company on the NASDAQ with ticker symbol LEXX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: LEXX . Sector: Health technology · USA

Products & Services of Lexaria Bioscience

Lexaria Bioscience offers a comprehensive portfolio of products and services, including DehydraTECH. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Platform enhances absorption of oral pharmaceuticals and reduces side effects

People of Lexaria Bioscience
Headcount 500-1000
Employee Profiles 4
Board Members and Advisors 10
Employee Profiles
People
Chris Bunka
Chairman & CEO
People
John Docherty
President and Director
People
Allan Spissinger
CFO & Corporate Secretary
People
George Jurčić
Head Of Investor Relations

Unlock access to complete

Board Members and Advisors
people
Julian Gangolli
Strategic Advisor
people
Catherine Turkel
Director
people
Terry D. Blumenthal
Advisor
people
Nicholas Baxter
Director

Unlock access to complete

Funding Insights of Lexaria Bioscience

  • Total Funding
  • Total Rounds 16
  • Last Round Post-IPO — $1.6M
  • First Round

    (29 Dec 2009)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2023 Amount Post-IPO - Lexaria Bioscience Valuation

investors

Dec, 2021 Amount Post-IPO - Lexaria Bioscience Valuation

investors

Jul, 2020 Amount Post-IPO - Lexaria Bioscience Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investments & Acquisitions by Lexaria Bioscience

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Lexaria Bioscience

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Lexaria Bioscience Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Lexaria Bioscience

Lexaria Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Focus Financial Partners, Alera Group, Avidity Biosciences, Sutro Biopharma and Wintrust, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Business consulting services are provided to banks and lending institutions.
domain founded_year HQ Location
HR, insurance, and liability services are provided by Alera Group.
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
domain founded_year HQ Location
Bank offering diversified financial services
domain founded_year HQ Location
Developing novel drugs based on a proteome-wide ligand and target discovery platform
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Lexaria Bioscience

Lexaria Awarded Six Additional Patents
The newswire.ca3 days ago
Lexaria Bioscience Corp. SEC 10-Q Report
TradingView11 days ago
Lexaria Releases Annual Letter from the CEO
The newswire.ca13 days ago

Frequently Asked Questions about Lexaria Bioscience

When was Lexaria Bioscience founded?

Lexaria Bioscience was founded in 2004 and raised its 1st funding round 5 years after it was founded.

Where is Lexaria Bioscience located?

Lexaria Bioscience is headquartered in Kelowna, Canada. It is registered at Kelowna, British Columbia, Canada.

Who is the current CEO of Lexaria Bioscience?

Chris Bunka is the current CEO of Lexaria Bioscience.

How many employees does Lexaria Bioscience have?

As of Aug 31, 2024, the latest employee count at Lexaria Bioscience is 7.

What is the annual revenue of Lexaria Bioscience?

Annual revenue of Lexaria Bioscience is $464.28K as on Aug 31, 2024.

What does Lexaria Bioscience do?

Lexaria Bioscience was founded in 2004 in Kelowna, Canada, within the biotechnology sector. Patented DehydraTECH technology is utilized for delivering fat-soluble active molecules and drugs, encompassing nicotine, NSAID pain-relievers, and other bioactives. Operations focus on formulation and delivery methods, with topical products such as patches, creams, and lotions also developed for administration.

Who are the top competitors of Lexaria Bioscience?

Lexaria Bioscience's top competitors include Sutro Biopharma, Focus Financial Partners and Alera Group.

What products or services does Lexaria Bioscience offer?

Lexaria Bioscience offers DehydraTECH.

Is Lexaria Bioscience publicly traded?

Yes, Lexaria Bioscience is publicly traded on NASDAQ under the ticker symbol LEXX.

What is Lexaria Bioscience's ticker symbol?

The ticker symbol of Lexaria Bioscience is LEXX on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available